

Immunoglobulin inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/IB87C6584A6CEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: IB87C6584A6CEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Immunoglobulin inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Immunoglobulin inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Immunoglobulin inhibitors Understanding

Immunoglobulin inhibitors: Overview

The interactions between immunoglobulin E (IgE) and its two receptors, Fc γ RI and CD23 (Fc γ RII), play pivotal roles in allergic disease. Fc γ RI is principally expressed on the surface of mast cells and basophils. Allergen mediated cross-linking of Fc γ RI-bound IgE on the surface of these IgE-sensitized cells triggers degranulation and release of inflammatory mediators. CD23 is expressed in membrane-bound (mCD23) and soluble forms, the latter existing as monomeric or trimeric fragments. Inhibiting the interaction between IgE and Fc γ RI, but not CD23, is thus a potentially promising therapeutic approach in the treatment of allergic disease.

The importance of immunoglobulin E (IgE) in atopic disorders such as asthma, allergic

rhinitis, food allergies, and atopic dermatitis is well established. Elevation of total serum IgE is typically found in many atopic patients, and in predisposed individuals, allergen-specific IgE is produced. The availability of humanized monoclonal antibodies against IgE has provided a new therapeutic option and tool to explore the role IgE in allergic diseases and the effects of inhibiting IgE itself. Clinically, anti-IgE therapy has already been proven to be useful in the treatment of asthma and allergic rhinitis.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Immunoglobulin inhibitors R&D. The therapies under development are focused on novel approaches for Immunoglobulin inhibitors.

Immunoglobulin inhibitors Emerging Drugs Chapters

This segment of the Immunoglobulin inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Immunoglobulin inhibitors Emerging Drugs

Ligelizumab: Novartis

Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody. Ligelizumab is thought to work by blocking the IgE/Fc γ RI pathway, a key driver of the inflammatory process in Chronic Spontaneous Urticaria (CSU). U.S. Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment.

It is currently in Phase III stage of development and is being developed by Novartis.

Further product details are provided in the report.....

Immunoglobulin inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Immunoglobulin inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Immunoglobulin inhibitors

There are approx. 5+ key companies which are developing the Immunoglobulin inhibitors. The companies which have their Immunoglobulin inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Immunoglobulin inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Immunoglobulin inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immunoglobulin inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immunoglobulin inhibitors drugs.

Immunoglobulin inhibitors Report Insights

- Immunoglobulin inhibitors Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Immunoglobulin inhibitors Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Immunoglobulin inhibitors drugs?

How many Immunoglobulin inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Immunoglobulin inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Immunoglobulin inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Immunoglobulin inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis

Yuhan

Hansa Biopharma

Epsilogen

Key Products

Ligelizumab

YH-35324

Imlifidase

MOv18 IgE

Contents

- Introduction
- Executive Summary
- Immunoglobulin inhibitors: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Ligelizumab: Novartis
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Drug Name: Company Name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- MOv18 IgE: Epsilogen
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Preclinical and Discovery Stage Products
 - Comparative Analysis

YH-35324: Yuhan

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Immunoglobulin inhibitors Key Companies

Immunoglobulin inhibitors Key Products

Immunoglobulin inhibitors- Unmet Needs

Immunoglobulin inhibitors- Market Drivers and Barriers

Immunoglobulin inhibitors- Future Perspectives and Conclusion

Immunoglobulin inhibitors Analyst Views

Immunoglobulin inhibitors Key Companies

Appendix

I would like to order

Product name: Immunoglobulin inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/IB87C6584A6CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IB87C6584A6CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970